عربي
By Dr. Sajjad Ali, Specialist Cardiologist | American Hospital Clinics Doha | QCHP P17304
Everyone in Doha is talking about Ozempic for weight loss. But cardiologists are excited about something else entirely.
GLP-1 receptor agonists — the drug class including semaglutide (Ozempic, Wegovy) — were developed for Type 2 diabetes, produced remarkable weight loss, and then delivered something cardiologists never expected: a 20% reduction in major cardiovascular events in a landmark five-year trial. At American Hospital Clinics Doha, Dr. Sajjad Ali assesses whether GLP-1 therapy is appropriate as part of an individualised cardiovascular risk management plan.
Discuss GLP-1 Therapy With Our Cardiologist
Book a Cardiology Consultation Today
What the Evidence Actually Shows
The SELECT trial followed over 17,000 patients with cardiovascular disease and obesity given semaglutide over five years. Result: a 20% reduction in major cardiovascular events (heart attack, stroke, or cardiovascular death) on top of existing standard medications. This is not a marginal finding.
Cardiovascular Benefits Beyond Weight Loss
✔ 20% reduction in major cardiovascular events — SELECT trial, 2023
✔ Reduced systolic blood pressure — consistent across multiple large trials
✔ Reduced C-reactive protein — direct reduction in arterial inflammation
✔ Improved kidney function — critical for diabetic patients at high cardiac risk
✔ Reduced heart failure hospitalisations — STEP-HFpEF trial 2023
Who Is This For in Qatar?
Qatar has among the highest rates of diabetes, obesity, and metabolic syndrome in the region. The typical patient who may benefit from GLP-1 therapy for cardiovascular reasons is extremely common here:
- Overweight or obese with Type 2 diabetes or prediabetes
- Existing cardiovascular disease — prior heart attack or stroke
- Elevated cholesterol and high blood pressure alongside metabolic risk
- Family history of heart disease with multiple risk factors
⚠ These are not lifestyle replacements. GLP-1 drugs require proper clinical assessment and monitoring. Self-prescribing or sourcing outside normal pharmacy channels is dangerous.
Clinical Assessment at American Hospital Clinics Doha
Dr. Sajjad Ali reviews your complete cardiovascular risk profile, existing medications, kidney function, and medical history to determine if GLP-1 therapy is appropriate for your case.
Medication Selection
The class contains several drugs at different doses with different approved indications. Ozempic, Wegovy, Victoza, and Saxenda each have specific uses. The right choice depends on whether your primary goal is diabetes control, weight management, or cardiovascular risk reduction.
Ongoing Monitoring
Regular review of kidney function, thyroid markers, and cardiovascular outcomes ensures safety and effectiveness — and dose adjustments are made based on your response.
Cardiovascular Risk Assessment — American Hospital Clinics Doha
Limited-time offer for first-time patients. Call +974 44038777 to confirm availability.
| Package Name | Includes | Price (QAR) |
|---|---|---|
| Metabolic & Cardiac Risk Package |
|
From 350 QAR |
| Full Body Health Checkup |
|
159 QAR |
| Easy Friday Health Checkup |
|
89 QAR |
| Wellness Checkup |
|
49 QAR |
Why Choose American Hospital Clinics Doha?
✔ Specialist Cardiologist assessment — not a GP prescription
✔ Comprehensive cardiovascular and metabolic risk evaluation
✔ Full workup including kidney function, lipids, and blood glucose
✔ Insurance authorisation support provided where applicable
✔ Ongoing monitoring and dose adjustment
✔ Most major Qatar insurance plans accepted
Your health is managed with precision, safety, and long-term care — by specialists who treat people, not just conditions.
Medically reviewed and endorsed by:
Doctor’s Review & Clinical Oversight
This content is reviewed and endorsed by:
Dr. Sajjad Ali
Specialist Cardiologist
QCHP License: P17304
American Hospital Clinics, Qatar
"Weight loss is almost a side effect. The primary story, from a cardiologist's perspective, is what these drugs are doing to heart attack and stroke rates. A 20% reduction in major cardiovascular events on top of existing treatment is the kind of finding that changes clinical guidelines — and patient lives."
First GLP-1 Cardiac Assessment — Special Rate This Month
LIMITED-TIME OFFER
New cardiology patients at American Hospital Clinics Doha receive a discounted first consultation for metabolic and cardiovascular risk assessment. Call +974 44038777 to book.
Limited time offer for first-time patients. Call +974 44038777 to confirm availability.
Why Choose American Hospital Clinics Doha?
✔ Specialist Cardiologist — Dr. Sajjad Ali, QCHP P17304
✔ ECG, echocardiography, and cardiac risk assessment available on-site
✔ Post-event follow-up and long-term heart management
✔ Same-day appointments available — don’t delay
✔ Male and female cardiology consultation services
✔ Most major Qatar insurance plans accepted
Your health is managed with precision, safety, and long-term care — by specialists who treat people, not just conditions.
What Our Patients in Doha Say
FAQs
Can I take GLP-1 drugs just for heart protection without diabetes?
Are GLP-1 drugs safe long-term?
Will Qatar insurance cover GLP-1 drugs for heart protection?
What is the difference between Ozempic and Wegovy?
How quickly do GLP-1 drugs show cardiovascular benefits?
Is this available at American Hospital Clinics Doha?
Book a GLP-1 Cardiac Assessment Today
A proper assessment always comes first. Find out if this therapy is right for your heart.
C Ring Road, Al Muntazah Street, Doha, Qatar
